宫颈癌患者血清可溶性B7-H4检测及临床意义

目的探讨宫颈癌患者血清可溶性B7-H4的水平及临床意义。方法在建立了检测可溶性B7-H4(sB7-H4)ELISA夹心法的检测50例宫颈癌患者、40例子宫肌瘤患者血清sB7-H4水平,以50例体检健康者血清sB7-H4水平为对照。结果正常体检者、子宫肌瘤患者和宫颈癌患者血清sB7-H4浓度分别为(31.62±9.85)μg/L(、34.49±8.17)μg/L和(43.70±8.60)μg/L。对照组者与子宫肌瘤患者血清sB7-H4水平差异无显著性(P0.05),宫颈癌患者血清sB7-H4水平显著高于对照组和子宫肌瘤患者(P均0.01)。手术前宫颈癌患者血清sB7-H4水平(46.88±8.89)μg/L明显高于术后患者(39.29±5.99)μg/L(P0.01)。宫颈癌患者血清sB7-H4水平与鳞状上皮癌肿瘤(SCC)水平呈正相关(P0.01)。结论 sB7-H4与宫颈癌的发病有关,可能是宫颈癌的一种较好的肿瘤标志物,检测sB7-H4对宫颈癌的辅助诊断和疗效观察具有一定的临床意义。

Clinical significance of determination of serum B7-H4 in patients with uterine cervix cancer

Objective To study the clinical significance of determination of serum B7-H4 in patients with uterine cervix cancer.Methods Serum B7-H4 levels were determined in 50 patients with uterine cervix cancer and 40 patients with uterine fibroid as well as in 35 controls.Results The serum B7-H4 levels in patients with uterine cervix cancer（43.70±8.60 μg/L） were significantly higher than those in patients with uterine fibroid（36.63±7.70 μg/L）and healthy controls（31.62±9.85 μg/L）（P0.01）.But the B7-H4 in serum were not significant between patients with uterine fibroid and healthy controls（P0.05）.The serum B7-H4 levels in patients with uterine cervix cancer before surgical treatment（46.65±8.59 μg/L）was higher than that in patients with uterine cervix cancer after surgical treatment（38.45±9.33 μg/L）（P0.01）.There was correlation between the serum B7-H4 levels in patients with uterine cervix cancer and the serum SCC levels in patients with uterine cervix cancer（P0.05）.Conclusion These results suggest that the B7-H4 may correlation with uterine cervix cancer.B7-H4 may be a new marker of diagnosis for uterine cervix cancer.Measurement of serum B7-H4,not only provide useful information for distinctive diagnosis of different kinds of uterine diseases,but also is a good target in evaluation of disease extent and effect of treatments in patients with uterine cervix cancer.